ClinicalTrials.gg
RecruitingNCT06780709NMOSDUpdated Nov 2, 2026

Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD

An interventional study of Wellness Program and Behavioral Counseling in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Nov 2, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Neuromyelitis Optica with a site in United States — 16 open to participants now, 21 under way, 2 of them phase 3. Neuromyelitis Optica · United States.

Planned enrollment
20th of 37
20 · median 22
Started
2025
with 2 others
No phase
7 of 52
4 open now
Primary completion
2028-01
later than 9 of 20 live
Registered
52nd of 52
by date
Lead sponsor
3 of 52
Icahn School of Medicine at Mount Sinai

Among the 52 studies in Neuromyelitis Optica with a site in United States, this one is the 20th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2025, is one of 7 with no phase, reaches primary completion later than 9 of the 20 other live ones, and was the 52nd registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

16 of the 52 studies in Neuromyelitis Optica with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Neuromyelitis Optica with a site in United States, or all of them as a file.
02

Study summary

This project aims to study whether a structured wellness program intervention can improve quality of life among people living with Neuromyelitis Optica Spectrum Disorder (NMOSD). This pilot will test a multi-modal wellness program tailored to NMOSD patients that includes services from physical therapists, dietitians, social workers, nurse practitioners and cognitive therapists. The trial will be designed as a randomized controlled trial, randomizing patients to immediately starting the program as well as a 6 month delayed start. The intervention would leverage an existing clinical comprehensive MS wellness program at the Corinne Dickinson for Multiple Sclerosis (MS) at Mount Sinai Medical Center. The primary endpoint of this study would be evaluating quality of life, as assessed by MS-Quality of Life -54.

Read the detailed description

This pilot will aim to recruit 20 patients. Participants will be randomized into one of two arms: the trial group will begin wellness program services and behavioral interventions immediately; the control group will participate in other educational activities, and begin wellness program services and behavioral interventions 6 months after randomization. The wellness intervention will include dietary, physical therapy, social work, and nurse practitioner evaluations, as well as behavioral counseling to implement recommendations. All participants will complete assessments, with patient-reported outcome surveys and objective assessments at baseline, 12 weeks, and 6 months for the core study. Participants will also be offered the option of continuing into a one year extension study, wherein one additional wellness intervention and bimonthly behavioral counseling sessions will be offered until 12 months on study. Study assessments will be completed at 12 months and 18 months to assess sustainability of the program. Assessments will include subjective reports of quality of life as pertaining to living with their disease, mobility, vision, exercise, diet, as well as objective measures of motor and vision function.

03

Conditions studied

  • Neuromyelitis Optica Spectrum Disorder (NMOSD)

Browse trials for

Keywords

  • NMOSD
  • Wellness
  • Diet
  • Physical Therapy
  • Social Work
  • Comprehensive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (age ≥18) with NMOSD diagnosed with 2015 NMOSD clinical criteria.
  • All EDSS scores will be considered in order to make the intervention accessible to all patients regardless of disability.
  • All patients regardless of treatment type will be considered.

Exclusion criteria

Exclusion criteria:

  • Age\<18
  • Inability to voluntarily provide consent for study participation
  • Inability to participate in study evaluation and/or endpoint measures, or participation in another concurrent randomized controlled trial or wellness based intervention.
  • Any patients with a relapse within 30 days of randomization or any patients with medical restrictions on physical activity will be excluded.
  • Any patients who begin stimulants and/or dalfampridine between enrollment and randomization will be excluded.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Immediate Start

    Participants will begin wellness program services and behavioral interventions immediately after randomization

    Behavioral: Wellness Program and Behavioral Counseling

  • Other
    Delayed Start

    Participants will experience a 6-month delay in receiving wellness program services and behavioral interventions.

    Behavioral: Wellness Program and Behavioral Counseling

Interventions

  • BehavioralWellness Program and Behavioral Counseling

    The comprehensive wellness evaluation will include initial assessments by dietician, social worker, physical therapist, nurse practitioner, and a behavioral neuropsychologist. Each provider will conduct an initial evaluation at baseline to identify areas of need and patient driven goals, as well as follow-up evaluations to evaluate implementation of changes and barriers to change.

06

What researchers measure

Primary outcomes

  1. Multiple Sclerosis Quality of Life (MSQOL-54) Score

    The MSQOL-54 is a 54-item comprehensive patient-reported questionnaire for individuals with MS. MSQOL-54 yields two main composite scores calculated using weighted averages of relevant areas: Physical Health Composite (PHC) - the physical function, health perceptions, energy/fatigue, role limitations- physical, pain, sexual function, social function, health distress scales. The Mental Health Composite (MHC) - the health distress, overall quality of life, emotional wellbeing, role limitations- emotional, cognitive function scales. Each composite scores range from 0-100, with total scale range from 0-100. Higher scores indicating better perceived health and quality of life. Lower scores suggest poorer quality of life impacted by MS. MSQOL-54 evaluates how MS affects various aspects of a patient's life and well-being, providing valuable insights into the patient's overall health status and the impact of MS on their daily functioning.

    Time frame: at baseline, 3 months, at 6 months, at 12 months for extension study, at 18 months for extension study

Secondary outcomes

  1. Impact of vision impairment (IVI) Score

    The Impact of Vision Impairment (IVI) is a 32-item patient-reported instrument measuring vision impairment's effect on quality of life and daily activities. The questionnaire assesses five domain subscales: Leisure and Work, Social and Consumer Interaction, Household and Personal Care, Mobility, and Emotional Reaction to Vision Loss. Items use a 6-point Likert scale (0: Not at all, 1: Hardly at all, 2: A little, 3: A fair amount, 4: A lot, 5: Can't do because of eyesight). Domain subscale scores are calculated as the mean of items within each domain, and the total score is the mean of all items. Subscales range from 0-5, with total scale range from 0-5. Lower scores indicating better vision-related quality of life. A decrease in scores represents improvement over time.

    Time frame: at baseline, 3 months, at 6 months, at 12 months for extension study, at 18 months for extension study

  2. Neuro-Quality of Life (Neuro-QOL) Score

    Neuro QOL (quality of life) subscales indicating upper extremity function, lower extremity function, executive function, ability to participate in social roles/activities, satisfaction with social roles and activities) will be assessed. Scores are assessed and compared to normative data, with a T score generated. T distributions assume a mean of 50, and the standard deviation is set to 10 units. A higher T score value indicates a greater deviation from normal functioning.

    Time frame: at baseline, 3 months, at 6 months, at 12 months for extension study, at 18 months for extension study

  3. The Godin Leisure Time and Exercise (GLTEQ) Score

    The GLTEQ is a patient reported scale assessing patient reported frequency of exercise in a typical 7-day period during their free time. Total Scale is weighted to calculate a composite score from 0-99, with a higher score indicating a more active lifestyle.

    Time frame: at baseline, 3 months, at 6 months, at 12 months for extension study, at 18 months for extension study

  4. Mediterranean Diet Compliance Scale (MEDAS)

    MEDAS questionnaire is a self-reported recall of food consumption. This is a 14-item questionnaire, with each item being scored as a 0 or 1 indicating consumption of the specified category of food, with a total scale range of 0-14. A higher score indicates a higher alignment with a mediterranean based diet.

    Time frame: at baseline, 3 months, at 6 months, at 12 months for extension study, at 18 months for extension study

07

Study locations

1 of 1 sites recruiting
  • Corinne Goldsmith Dickinson Center for MS at Mount Sinai
    New York, New York 10029, United States
    Recruiting
    • Sammita Satyanarayan · Principal investigator
    • Ilana Katz-Sand, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Dataset includes sensitive data such as substance use (from dietary surveys) and mental health status.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Jan 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 17, 2025
StartActual
Jan 28, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jan 21, 2025→Jan 28, 2025
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Jan 21, 2025→Jan 28, 2025
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06780709
Responsible party
Sammita Satyanarayan (Assistant Professor, Neurology, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Jan 17, 2025
Start date
Jan 28, 2025
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Susan Filomena
Contact
susan.filomena@mssm.edu
212-241-3841
Savannah Steer
Contact
savannah.steer@mssm.edu
212-241-4264
Sammita Satyanarayan, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion